DRUG · Mapped RxNorm record
Trilaciclib
Normalized identity: trilaciclibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
NCT02514447
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Topotecan
Normalized identity: topotecanView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedTrilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
TrilaciclibDRUG · verified · RxNorm: trilaciclib
PlaceboDRUG
TopotecanDRUG · verified · RxNorm: topotecan
Sponsors & collaborators
G1 Therapeutics, Inc.lead sponsor
Mapped research locations
BelgradeSerbia3HoustonTexas, United States2AtlantaGeorgia, United States2NashvilleTennessee, United States2TylerTexas, United States2ZagrebCroatia2DallasTexas, United States1DenverColorado, United States1Oklahoma CityOklahoma, United States1SacramentoCalifornia, United States1Kansas CityMissouri, United States1GreenvilleSouth Carolina, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02514447 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.